News for Bright Minds Biosciences Inc. (BMBIF)

May 21, 2025 ”“ Bright Minds Biosciences (DRUG) has received a reaffirmed 'Buy' rating from Chardan Capital analyst Rudy Li. The pharmaceutical company continu

On May 13, 2025, Bright Minds Biosciences, listed under the ticker DRUG, received a significant update as TD Cowen initiated coverage of the company with a 'Buy

On May 7, 2025, Chardan Capital initiated coverage on Bright Minds Biosciences (DRUG), providing a 'Buy' rating for the stock. The analyst responsible for this

VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) ( DRUG) (”œBright Minds” or the ”œCompany”), a

”“ Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in

NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (”œBright Minds,” ”œBMB” or the ”œCompany”

Significant Transaction by COMMODORE CAPITAL LP (Trades, Portfolio) On December 31, 2024, COMMODORE CAPITAL LP (Trades, Portfolio) executed a noteworthy transac

On January 31, 2025, JANUS HENDERSON GROUP PLC (Trades, Portfolio) made a significant move by acquiring 804,976 shares of Bright Minds Biosciences Inc (NASDAQ:

Bright Minds' phase 2 trial for Absence Epilepsy and DEE could have data released by 2026. Read why investors could benefit from DRUG stock.

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiation...

**media[507887]**

-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIR

Stocks Analysis by Professor Ari Zoldan covering: US Small Cap 2000, Alexion Pharmaceuticals Inc, AstraZeneca PLC ADR, Monopar Therapeutics Inc. Read Professor Ari Zoldan's latest article on Investing.com

AIFF Stock Touches 52-Week Low at $2.69 Amid Market Challenges

- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Brigh

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ('Bright Minds” or the 'Company”) announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company ('Shares”) at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the 'Offering”).

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“

Overview of the Recent Transaction On October 16, 2024, Steven Cohen (Trades, Portfolio), through Point72 Asset Management, made a significant new investment in

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.09%